PBAC's latest decision on Dapagliflozin and metformin extended release: Recommended with restriction (2015). Considered for Treatment of type 2 diabetes mellitus in adults as add-on to insulin therapy or as triple oral therapy in combination with a sulfonylurea.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2014
Submissions
2
2014 → 2015
Eligible population
Adults with type 2 diabetes mellitus inadequately controlled on insulin with oral antidiabetic agents (for add-on to insulin setting) or on metformin and a sulfonylurea (for triple oral therapy setting), with HbA1c greater than 7% or blood glucose levels greater than 10 mmol/L in more than 20% of tests over 2 weeks.
Therapy area
Endocrinology
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis based on bioequivalence; no ICER calculated.
Submission history
Jul 2014: Noted · Authority Required
Jul 2015: Recommended with restriction · Authority Required